topic

395 Enhancement of bispecific T cell engagers (bispecific TCE) killing potency in AML with the neximmune artificial immune modulation (AIM™) adoptive cell therapy (ACT) T cells
Ruipeng Wang, Mathias Oelke, Shweta Jain, Sojung Kim, Jack Ragheb, Adam Parks, Rui Wang, Charles Reed, Brian Alvarez, Jerome Zeldis, Daniel Bednarik

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A443; DOI: 10.1136/jitc-2023-SITC2023.0395
396 Artificial Immune Modulation (AIM) nanoparticles expand antigen specific CD8 T cells from both naïve and memory T cell populations
Ruipeng Wang, Lauren Suarez, Bryan Hahn, Alison Farrell, Sojung Kim, Mathias Oelke

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A444; DOI: 10.1136/jitc-2023-SITC2023.0396
397 Targeting glycans to enhance adoptive cell therapy
Peng Wu, James C Paulson, Eleanor Bashian

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A445; DOI: 10.1136/jitc-2023-SITC2023.0397
398 Utilizing a Th17 polarization strategy for generating high quality human TIL products for patients with advanced solid tumors
Megan M Wyatt, Hannah M Knochelmann, Michael C Lowe, Keith A Delman, Soundharya Kumaresan, Gregory B Lesinski, Chrystal M Paulos

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A446; DOI: 10.1136/jitc-2023-SITC2023.0398
399 Class I HLA-independent lysis of cancer cells by tumor-infiltrating CD8 T cells
Hongyan Xie, Aiping Jiang, Jonathan Perera, Moshe Sade-Feldman, Nir Hacohen, Robert T Manguso, Russell W Jenkins

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A447; DOI: 10.1136/jitc-2023-SITC2023.0399
400 Preclinical characterization and modelling of allogeneic Vγ9Vδ2 TAC T cells for the treatment of solid tumors
Stacey X Xu, Suzanna L Prosser, Ling Wang, Ritu R Randhawa, Sailaja Pirati, Deepika Bhemarasetty, Kyle MacDonald, Seung Mi Yoo, Miyoung E Jung, Laurentia A Gheorghiu, Chris L Ayers, Sadhak Sengupta, Christopher W Helsen, Andreas G Bader

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A448; DOI: 10.1136/jitc-2023-SITC2023.0400
401 GDA-201, nicotinamide (NAM) expanded NK cells derived from peripheral apheresis, show unique culture kinetics and increased expansion
Avner Yeffet, Isabelle Solomon, Moriya Gamliel, Yaron Meirow, Eliran Arbib, Dima Yackoubov, Avishay Edri, Yael Yoffe-Mizrahi, Ronit Simantov, Yona Geffen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A449; DOI: 10.1136/jitc-2023-SITC2023.0401
402 Mitophagy reinvigorates exhausted CD8 T cell
Ruohan Zhang, Nuo Sun, Gang Xin

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A450-A451; DOI: 10.1136/jitc-2023-SITC2023.0402
403 Tumor-infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro
Yongliang Zhang, Nathan Gilbert, Patrick Innamarato, Judy Fang, Hequn Yin

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A452; DOI: 10.1136/jitc-2023-SITC2023.0403
404 Impact of PSMA antibody or chimeric antigen receptor on phagocytosis and tumor localization by wild-type and NF-κB p50-deficient macrophages
Mohammad A Alzubi, Theresa Barberi, Alan D Friedman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A453; DOI: 10.1136/jitc-2023-SITC2023.0404

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages